98%
921
2 minutes
20
Background: The intraindividual difference between the estimated glomerular filtration rates by cystatin C and creatinine (ie, eGFRdiff) is of clinical importance. This study aimed to investigate the cross-sectional and longitudinal associations of eGFRdiff with stroke using nationally representative data from the CHARLS (China Health and Retirement Longitudinal Study).
Methods: This study included 11 869 participants (aged ≥45 years) from the CHARLS 2015 for the cross-sectional analysis. A total of 11 553 participants free of stroke were recruited in 2015 as baseline and followed up to 2020 for the cohort analysis. The eGFRdiff was calculated by subtracting estimated glomerular filtration rate by serum creatinine from estimated glomerular filtration rate by serum cystatin C at baseline. Logistic regression models and Cox proportional hazards models were used to examine the cross-sectional and longitudinal associations.
Results: The mean age of the participants was 60.3±9.6 years, and 5514 (46.5%) were men. According to the cross-sectional analysis, a negative eGFRdiff was associated with a greater prevalence of stroke (odds ratio per 1 SD, 0.841 [95% CI, 0.741-0.955]). During a median follow-up of 5.0 years, 838 individuals (7.3%) experienced incident stroke. A lower baseline eGFRdiff was associated with a greater risk of stroke onset (hazard ratio [HR] per 1 SD, 0.884 [95% CI, 0.817-0.955]). Compared with those in the midrange eGFRdiff group (from -15 to 15 mL/min per 1.73 m), those in the negative eGFRdiff group (<-15 mL/min per 1.73 m) exhibited a significantly increased risk of incident stroke (HR, 1.202 [95% CI, 1.026-1.407]).
Conclusions: A large negative eGFRdiff was independently associated with higher prevalence and incidence rates of stroke among middle-aged and older Chinese adults.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229175 | PMC |
http://dx.doi.org/10.1161/JAHA.124.039185 | DOI Listing |
Clin J Am Soc Nephrol
September 2025
The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Background: Substantial advances have been made in therapeutics for IgA nephropathy. We conducted a systematic review and meta-analysis to evaluate the comparative efficacy and safety of existing and novel IgA nephropathy therapies.
Methods: We searched MEDLINE and Embase databases from inception to May 21, 2025 for Phase 2b and 3 multi-center, randomized, placebo-controlled trials enrolling patients with IgA nephropathy that reported treatment effects on proteinuria and/or estimated glomerular filtration rate (eGFR) slope.
MedComm (2020)
September 2025
Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerulonephritis globally, is characterized by mesangial IgA deposition and heterogeneous clinical trajectories. Historically, management relied on renin-angiotensin system inhibition and empirical immunosuppression, yet high lifetime kidney failure risk persists despite optimized care. This review synthesizes advances in molecular pathogenesis, highlighting how the traditional multi-hit hypothesis-while foundational for targeted therapy development-fails to capture IgAN's recurrent, self-amplifying nature.
View Article and Find Full Text PDFClin Kidney J
September 2025
Prof Department of Advanced Medical and Surgical Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Anemia and iron deficiency (ID) are common and significant complications in kidney transplant recipients (KTRs) that can affect their health-related quality of life (HRQoL) and outcomes. Current anemia guidelines equate the post-transplant situation with the anemia associated with chronic kidney disease (CKD) in non-transplanted persons, not acknowledging relevant differences ranging from pathophysiology to clinical manifestation. Nephrologists caring for these patients tend to pay less attention to post-transplant anemia (PTA) and ID than in non-transplanted persons with CKD.
View Article and Find Full Text PDFClin Kidney J
September 2025
Service Nephrologie Dialyse Apherese, Hopitale Universitaire de Nimes, France.
Background: The Kidney Failure Risk Equation (KFRE) is a prognostic score for predicting kidney replacement therapy (KRT) at 5 years in patients with chronic kidney disease (CKD). Some studies show that the score performs poorly for certain etiologies of CKD but not all have been evaluated. The aim of this study was to evaluate the performance of the KFRE score according to the etiology of the CKD.
View Article and Find Full Text PDFClin Kidney J
September 2025
Department of Nephrology and Institute of Nephrology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Background: This study aimed to evaluate the efficacy and safety of telitacicept versus mycophenolate mofetil (MMF) in high-risk progressive immunoglobulin A nephropathy (IgAN).
Methods: This retrospective, multicentre cohort study included patients with high-risk progressive IgAN who received telitacicept or MMF therapy, both combined with low-dose steroids. Clinical data were collected from treatment initiation to 12 months.